Authors
Mashael Alzahrani, Douaa Sindi, Saeed M G Al-Ghamdi, Naser Omran Odah, Rana Alghamdi, Ahmed Alrefaei
Published in
Kidney diseases (Basel, Switzerland). Volume 12. Issue 1. Pages 842-853. Epub Aug 05, 2026.
Abstract
Chronic hyperkalemia in patients with chronic kidney disease (CKD) often limits the use of vital renin-angiotensin-aldosterone system inhibitors (RAASi).
This prospective cohort study compared the efficacy and safety of patiromer (n = 40) versus sodium polystyrene sulfonate (SPS) (n = 40) for chronic hyperkalemia management in 80 adult CKD patients.
Over a 6-month follow-up, both agents effectively reduced serum potassium from similar baseline levels (patiromer: 5.73 ± 0.59 mmol/L; SPS: 5.62 ± 0.50 mmol/L) with no significant difference in efficacy (p > 0.05). However, key differences in the clinical impact on RAASi therapy emerged, alongside numerical but statistically nonsignificant differences in tolerability. Patients receiving patiromer had a significantly lower rate of RAASi therapy discontinuation compared to the SPS group (5.2% vs. 36.3%; p = 0.033), enabling continuation of guideline-directed medical therapy. A trend towards poorer compliance was noted in the SPS group (22.5% vs. 7.5%; p = 0.060). An exploratory analysis revealed that patiromer initiation significantly increased tacrolimus levels in post-kidney transplant recipients (p = 0.003), necessitating dose adjustments.
While both agents showed comparable potassium-lowering efficacy, patiromer's numerical advantages in tolerability and significant benefit in maintaining RAASi therapy position it as a valuable therapeutic option in this high-risk population.
PMID:
42877862
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0